|Articles|March 1, 2017
March 2017: Big Data, Big Opportunity in Life Sciences
Author(s)LexisNexis
The big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
Advertisement
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market
2
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
3
Positioning A New Standard of Care in Relapsed Multiple Myeloma: Q&A with Imran Khan, MD, PhD
4
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
5